Novo Nordisk secured U.S. approval for its oral GLP-1 weight-loss pill in December and immediately launched the product nationwide. In the first full week post-launch, the therapy recorded 18,410 prescriptions, according to IQVIA data shared by an industry analyst. This rapid uptake underscores strong demand for a needle-free alternative and leverages the company’s broad sales network, which spans more than 60,000 healthcare provider accounts.

Since the analyst’s last coverage, Novo Nordisk’s share price has climbed roughly 30%, reflecting renewed investor confidence in the company’s growth trajectory. Trading volumes remain elevated compared with the six-month average, signaling that institutional and retail buyers are positioning for sustained momentum. Sentiment surveys indicate that bullish sentiment now outweighs bearish views by nearly 2.5 to 1, the widest margin seen in over a year.

First-mover status in the oral GLP-1 category gives Novo Nordisk a durable advantage as competitors prepare their own candidates. The company’s R&D pipeline includes multiple follow-on obesity and diabetes therapies at various stages of clinical development, potentially extending patent life and addressing adjacent metabolic conditions. Combined with an efficient manufacturing footprint and ongoing cost-management initiatives that have kept gross margins above 80%, Novo Nordisk is poised to defend its leadership even as pricing pressures intensify in global markets.